

1 **Title:** Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among  
2 previously infected or vaccinated employees

3

4 **Authors:** Kojima N, MD<sup>1</sup>; Roshani A, PhD<sup>2</sup>; Brobeck M, BS<sup>2</sup>; Baca A, MD<sup>2</sup>; and  
5 Klausner JD, MD MPH<sup>3</sup>

6

7 <sup>1</sup> Department of Medicine, University of California Los Angeles, Los Angeles, 90095

8 <sup>2</sup> Curative Inc., San Dimas, CA

9 <sup>3</sup> Department of Population and Public Health Sciences, University of Southern  
10 California, Keck School of Medicine, Los Angeles, 90033

11

12 **Keywords:** COVID-19; SARS-CoV-2; Incidence; Reinfection; Prior Infection;  
13 Vaccination

14

15

16

17

18

19

20

21 **Corresponding Author Contact Information:**

22 Department of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA

23 90095. Email: [nkojima@ucla.edu](mailto:nkojima@ucla.edu)

24

25 **Abstract (Words 350)**

26 **Introduction:** The protective effect of previous infection versus vaccination is poorly  
27 studied. Among a clinical laboratory that has been conducting routine workforce  
28 screening since the beginning of the pandemic, we aimed to assess the relative risk of  
29 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection among  
30 individuals who were SARS-CoV-2 naïve, previously infected, or vaccinated.

31 **Methods:** Using an electronic laboratory information system, employees were divided  
32 into three groups: (1) SARS-CoV-2 naïve and unvaccinated, (2) previous SARS-CoV-2  
33 infection, and (3) vaccinated. Person-days were measured from the date of the  
34 employee first test and truncated at the end of the observation period. SARS-CoV-2  
35 infection was defined as two positive SARS-CoV-2 PCR tests in a 30-day period.  
36 Individuals with fewer than 14 days of follow up were excluded. Incidence estimates and  
37 the 95% confidence intervals were calculated using the Poisson Exact equation. The  
38 incidence rate ratio (IRR) was used as a measure of association between groups.  
39 Analyses were performed on StataSE (StataCorp, College Station, TX).

40 **Results:** We identified 4313, 254 and 739 employee records for groups 1, 2, and 3,  
41 respectively. The median age of employees was 29.0 years (interquartile range: 23.6,  
42 39.9). During the observation period, 254, 0, and 4 infections were identified among  
43 groups 1, 2, and 3, respectively. Group 1 had an incidence of 25.9 per 100 person-  
44 years (95% CI: 22.8-29.3). Group 2 had an incidence of 0 per 100 person-years (95%  
45 CI: 0-5.0). Group 3 had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2).  
46 The IRR of reinfection among those with previous infection compared to SARS-CoV-2  
47 naïve was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to SARS-CoV-2

48 naïve was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to prior  
49 SARS-CoV-2 was 0 (95% CI: 0-4.98).

50 **Conclusion:** Previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were  
51 associated with decreased risk for infection or re-infection with SARS-CoV-2 in a  
52 routinely screened workforce. There was no difference in the infection incidence between  
53 vaccinated individuals and individuals with previous infection. Further research is  
54 needed to determine whether our results are consistent with the emergence of new  
55 SARS-CoV-2 variants.

56

57 **Main Text (930 words)**

58 **Introduction**

59 Prior reports have found lower rates of Severe Acute Respiratory Syndrome  
60 Coronavirus-2 (SARS-CoV-2) infections among those with prior infection or  
61 vaccination.<sup>1, 2</sup> Although an association between vaccination and reduction of SARS-  
62 CoV-2 incidence has been well described, how the incidence among individuals with  
63 previous infection compares to vaccinated individuals remains unclear.

64

65 **Methods**

66 In March 2020, Curative, a SARS-CoV-2 testing company, began routinely screening its  
67 workforce with an Food and Drug Administration-authorized SARS-CoV-2 polymerase  
68 chain reaction (PCR)-based test.<sup>3</sup> The workforce was screened daily. A standardized  
69 employee testing database was implemented on 8 May 2020. On December 15, 2020,  
70 vaccination with either the BNT162b2 or mRNA-1273 vaccines became available.  
71 Routine screening has continued through July 2021.

72

73 The SARS-CoV-2 naïve, unvaccinated group was defined as any employee without  
74 previous infection that tested from 8 May up to 15 December 2020 (when vaccination  
75 became available). The previously infected, unvaccinated group was defined as any  
76 employee with documented previous SARS-CoV-2 infection (at least 2 positive PCR  
77 tests) between 8 May to 15 December 2020. The vaccinated group was defined as any  
78 employee with documented completion of vaccination through 1 July 2021.

79

80 Person-days were measured from the first test date to last test date up to December  
81 15<sup>th</sup>, 2020 for groups 1 and 2 and up to July 1, 2021 for group 3. We defined SARS-  
82 CoV-2 infection as two positive PCR tests in a 30-day period. Individuals with fewer  
83 than 14 days of follow up were excluded. Incidence in 100 person-years with 95%  
84 confidence intervals (95% CIs) was calculated with the Poisson Exact equation. The  
85 incidence rate ratio (IRR), the ratio of confirmed COVID-19 cases per 100 person-years  
86 of follow up with 95% CIs, was used as a measure of association between groups.  
87 Analyses were performed on StataSE (StataCorp, College Station, TX). The study of  
88 de-identified electronic medical record data was determined by the Advarra institutional  
89 review board (Pro00054560) to be exempt from review.

90

## 91 **Results**

92 We identified 4313, 254 and 739 employee records for the naïve and unvaccinated  
93 group (Group 1), the previously infected and unvaccinated group (Group 2) and the  
94 vaccinated without previous infection group (Group 3), respectively. The median age of  
95 employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation  
96 period, 254, 0, and 4 SARS-CoV-2 incident infections were identified among Groups 1,  
97 2, and 3, respectively. (Table).

98

99 The naïve, unvaccinated group had a SARS-CoV-2 incidence of 25.9 per 100 person-  
100 years (95% CI: 22.8-29.3). The previously infected, unvaccinated group had an  
101 incidence of 0 per 100 person-years (95% CI: 0-5.0). The vaccinated group had an  
102 incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR of reinfection among

103 those with previous infection compared to those SARS-CoV-2 naïve was 0 (95% CI: 0-  
104 0.19). The IRR of those vaccinated compared to those SARS-CoV-2 naïve was 0.06  
105 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to those previously SARS-  
106 CoV-2 infected was 0 (95% CI: 0-4.98).

107

## 108 **Discussion**

109 In the workplace setting, we observed a lower incidence of SARS-CoV-2 infection  
110 among those with previous SARS-CoV-2 infection or SARS-CoV-2 vaccination with  
111 either the BNT162b2 or mRNA-1273 vaccines. Either prior infection or vaccination was  
112 associated with a dramatic decreased risk for infection or re-infection with SARS-CoV-2.  
113 There was no difference in the incidence of SARS-CoV-2 infection or re-infection between  
114 individuals who were vaccinated and individuals with prior SARS-CoV-2 infection,  
115 respectively.

116

117 Our findings are similar to other studies that compared the incidence of SARS-CoV-2  
118 infection among those with prior SARS-CoV-2 infection and vaccination to unvaccinated  
119 antibody seronegative individuals. In a study conducted in Oxfordshire, UK, researchers  
120 reported that they found no differences in immunity induced by natural infection and  
121 vaccination with the BNT162b2 or ChAdOx1 nCoV-19 vaccines among a cohort of  
122 13,109 healthcare workers.<sup>4</sup> Another group of researchers studying a group of 52,238  
123 employees of the Cleveland Clinic Health System found that those with previous SARS-  
124 CoV-2 infection and those who were vaccinated had lower rates of SARS-CoV-2  
125 infection compared to those who were SARS-CoV-2 naïve and unvaccinated.<sup>5</sup>

126

127 After vaccination or natural infection, many mechanisms of immunity exist including  
128 humoral and cellular immunity.<sup>6-8</sup> It is known that SARS-CoV-2 infection induces specific  
129 and durable T cell immunity against multiple SARS-CoV-2 spike (S) protein targets (or  
130 epitopes) as well recognition of other SARS-CoV-2 proteins. The broad diversity of T-  
131 cell viral recognition serves to enhance protection to SARS-CoV-2 variants,<sup>7</sup> with  
132 recognition of at least three SARS-CoV-2 variants (B.1.1.7 [U.K.], B.1.351 [South Africa],  
133 and B.1.1.248 [Brazil]).<sup>9</sup> Additionally, a memory B cell response to SARS-CoV-2 evolves  
134 between 1.3 and 6.2 months after infection that is consistent with immune persistence.<sup>10</sup>

135

136 Our findings were limited by the observational nature of the study. It is possible, but  
137 unlikely, that employees could have tested positive outside of the employee testing  
138 program. In addition, because allocation to each exposure group was not random, there  
139 might be differences between groups in the risk of repeat exposure over time. The study  
140 was strengthened by the high incidence among those naïve and unvaccinated, the large  
141 sample size and large number of person-years of follow up in each group.

142

### 143 **Conclusion**

144 We found a strong association between prior SARS-CoV-2 infection and vaccination for  
145 SARS-CoV-2 with either BNT162b2 or mRNA-1273 and the reduced incidence of  
146 SARS-CoV-2 when compared to those naïve and unvaccinated to SARS-CoV-2. The  
147 was no difference in the incidence of SARS-CoV-2 between individuals who were  
148 vaccinated and individuals with prior SARS-CoV-2 infection. Combined with prior

149 studies, our findings should provide increased confidence that those previously infected  
150 are at very low risk for repeat infection. Further research is needed to determine  
151 whether our results are consistent with the emergence of new SARS-CoV-2 variants.

152

### 153 **Declarations**

154 Declaration of competing interests

155 NK is a consultant for Curative. AR, MB, and AB are employed by Curative. JDK is an  
156 independent consultant and serves as the Medical Director of Curative.

157

### 158 **Funding**

159 None

160

### 161 **Acknowledgements**

162 The staff at Curative Inc.

163 **References**

- 164 1. Qureshi AI, Baskett WI, Huang W, et al. Re-infection with SARS-CoV-2 in  
165 Patients Undergoing Serial Laboratory Testing. *Clin Infect Dis.* Apr 25  
166 2021;doi:10.1093/cid/ciab345
- 167 2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a  
168 Nationwide Mass Vaccination Setting. *N Engl J Med.* Apr 15 2021;384(15):1412-1423.  
169 doi:10.1056/NEJMoa2101765
- 170 3. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swab  
171 Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal  
172 Swab Specimens for the Detection of SARS-CoV-2. *Clin Infect Dis.* Oct 19  
173 2020;doi:10.1093/cid/ciaa1589
- 174 4. Lumley SF, Rodger G, Constantinides B, et al. An observational cohort study on  
175 the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare  
176 workers by antibody and vaccination status. *Clin Infect Dis.* 2021;  
177 doi:10.1093/cid/ciab608
- 178 5. Shrestha NK, Burke PC, Nowacki AS, et al. Necessity of COVID-19 vaccination  
179 in previously infected individuals. *medRxiv.* 2021; doi:10.1101/2021.06.01.21258176
- 180 6. Doshi P. Covid-19: Do many people have pre-existing immunity? *Bmj.* Sep 17  
181 2020;370:m3563. doi:10.1136/bmj.m3563
- 182 7. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity  
183 in cases of COVID-19 and SARS, and uninfected controls. *Nature.* Aug  
184 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z

- 185 8. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2  
186 infection in humans: A systematic review. *PloS one*. 2021;16(1):e0245532.  
187 doi:10.1371/journal.pone.0245532
- 188 9. Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19  
189 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-  
190 2 circulating variants. *medRxiv*. Feb 12 2021;doi:10.1101/2021.02.11.21251585
- 191 10. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-  
192 CoV-2. *Nature*. Mar 2021;591(7851):639-644. doi:10.1038/s41586-021-03207-w  
193

194 **Table.** Incidence of COVID-19 in 100 person-years (PY) by initial infection, reinfection, and initial infection among  
 195 vaccinated persons in a workforce, Los Angeles County, 2020-2021

Infections	<u>Cohort size</u>	<u>Total infections</u>	<u>Incidence per 100 PY and 95% CI*</u>	<u>Follow up time in PY</u>
Initial infection	4313	254	25.9 (22.8-29.3)	979.7
Reinfection	254	0	0 (0-5.0)	74.4
Infections among those vaccinated	739	4	1.6 (0.04-4.2)	244.5

196 \* Poisson Exact was used to calculate 95% Confidence Interval